Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
Por:
Martin M, Garcia-Saenz JA, Manso L, Llombart A, Cassinello A, Atienza M, Ringeisen F and Ciruelos E
Publicada:
1 nov 2020
Ahead of Print:
1 ago 2020
Resumen:
The addition of CDK4 and 6 inhibitors (abemaciclib, palbociclib or ribociclib) to endocrine therapy, as first-line treatment or following progression after initial endocrine therapy, significantly increased progression-free survival, objective response rates and in some trials overall survival, compared with endocrine therapy alone in HR+ and HER2- breast metastatic breast cancer. These CDK4 and 6 inhibitors are now approved in this context and have become a new standard of care. A hypothesis-generating exploratory analysis suggested that the addition of abemaciclib to endocrine therapy showed the largest effects in subgroups of women with indicators of poor prognosis, although these data require confirmation. This review provides updated clinical trial data for all three drugs in metastatic breast cancer, focusing on abemaciclib, the most recently approved agent.
Filiaciones:
Martin M:
Gregorio Marañon Health Research Institute, Universidad Complutense, CIBERONC, Dr. Esquerdo 46, 28006 Madrid, Spain
Garcia-Saenz JA:
Medical Oncology Department, Hospital Clínico San Carlos Health Research Institute (IdISSC), 28040 Madrid, Spain
Manso L:
Medical Oncology Department, 12 de Octubre University Hospital, Avda Andalucia s/n., 28041 Madrid, Spain
:
Medical Oncology Department, Arnau de Vilanova Hospital, FISABIO, Universidad Católica Valencia, San Clemente 12, 46015 Valencia, Spain
Cassinello A:
Eli Lilly & Company, Av. de la Industria 30, 28108 Alcobendas, Spain
Atienza M:
Eli Lilly & Company, Av. de la Industria 30, 28108 Alcobendas, Spain
Ringeisen F:
Eli Lilly Export SA, 16, Ch. Des Coquelicots, CH-1214 Vernier, Switzerland
Ciruelos E:
Breast Cancer Unit, Medical Oncology Department, 12 de Octubre University Hospital, HM CIOCC, 28041 Madrid, Spain
hybrid
|